(Q35621665)

9 August 2017

1 reference

title

Safety of immunization and adverse events following vaccination against hepatitis B. (English)

1 reference

9 August 2017

Philippe Duclos

1

1 reference

9 August 2017

language of work or name

1 reference

1 January 2003

1 reference

9 August 2017

published in

Journal of Hepatology

1 reference

9 August 2017

volume

39 Suppl 1

1 reference

9 August 2017

page(s)

S83-8

1 reference

Status of hepatitis B immunization programmes in 1998

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900153-3

7 January 2021

Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900153-3

7 January 2021

Seroepidemiologic survey for hepatitis B virus infection in Taiwan: the effect of hepatitis B mass immunization

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900153-3

7 January 2021

Hepatitis B vaccine and central nervous system demyelinating diseases. Viral Hepatitis Prevention Board

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900153-3

7 January 2021

Overview of clinical studies with hepatitis B vaccine made by recombinant DNA

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900153-3

7 January 2021

Yeast-recombinant hepatitis B vaccine. Efficacy with hepatitis B immune globulin in prevention of perinatal hepatitis B virus transmission

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900153-3

7 January 2021

Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900153-3

7 January 2021

The prevention of hepatitis B with vaccine. Report of the centers for disease control multi-center efficacy trial among homosexual men

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900153-3

7 January 2021

Safety of neonatal hepatitis B vaccine administration

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900153-3

7 January 2021

Hair loss after routine immunizations

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900153-3

7 January 2021

The timing of immunization affects the development of diabetes in rodents

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900153-3

7 January 2021

Association between type 1 diabetes and Haemophilus influenzae type b vaccination: birth cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900153-3

7 January 2021

No evidence that vaccines cause insulin dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900153-3

7 January 2021

Childhood immunizations and type 1 diabetes: summary of an Institute for Vaccine Safety Workshop. The Institute for Vaccine Safety Diabetes Workshop Panel

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900153-3

7 January 2021

Adverse events associated with hepatitis B vaccine in U.S. children less than six years of age, 1993 and 1994.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900153-3

7 January 2021

Hepatitis B vaccine and first episodes of central nervous system demyelinating disorders: a comparison between reported and expected number of cases

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900153-3

7 January 2021

Vaccinations and the risk of relapse in multiple sclerosis. Vaccines in Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900153-3

7 January 2021

No increase in demyelinating diseases after hepatitis B vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900153-3

7 January 2021

School-based hepatitis B vaccination programme and adolescent multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900153-3

7 January 2021

Hepatitis B vaccination and the risk of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900153-3

7 January 2021

Postmarketing surveillance for neurologic adverse events reported after hepatitis B vaccination. Experience of the first three years

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900153-3

7 January 2021

Central-nervous-system demyelination after immunisation with recombinant hepatitis B vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900153-3

7 January 2021

Transverse myelitis following hepatitis B vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900153-3

7 January 2021

Multiple sclerosis and hepatitis B vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900153-3

7 January 2021

Two episodes of leukoencephalitis associated with recombinant hepatitis B vaccination in a single patient.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900153-3

7 January 2021

The process of public policy formulation: the case of thimerosal in vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900153-3

7 January 2021

10.1016/S0168-8278(03)00153-3

Identifiers

DOI

1 reference

9 August 2017

1 reference